Rituximab vs placebo
Mean improvement in disability · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
1 finding from 1 review
- Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies 2016 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 73 participantsLow